SCHEMBL29975976

SCHEMBL29975976

CP(C)(=O)c1cc(-c2ccccc2)ccc1Nc1nc(Cl)ncc1Br

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 3/20 0.42
▸ IGF1R P08069 9/20 0.40
▸ ALK Q9UM73 7/20 0.39
▸ INSR P06213 6/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CDK7 P50613 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ ABL1 P00519 1/20 0.37
▸ BCR P11274 1/20 0.37
▸ ZAP70 P43403 1/20 0.36
▸ MAPK8 P45983 1/20 0.35
▸ CDK19 Q9BWU1 1/20 0.35
▸ MAP4K1 Q92918 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23153875 1.00 EGFR (0.42) EGFRIGF1RALKINSRMEN1
SCHEMBL23154090 0.89 INSR (0.49) EGFRIGF1RALKINSRCDK7
SCHEMBL23153748 0.88 EGFR (0.41) EGFRIGF1RALKINSRMEN1
SCHEMBL23154179 0.88 ALK (0.40) EGFRIGF1RALKINSRCDK7
SCHEMBL23154176 0.87 MEN1 (0.36) EGFRIGF1RALKINSRMEN1
SCHEMBL23153853 0.87 EGFR (0.40) EGFRIGF1RALKINSRMEN1
SCHEMBL23153842 0.87 EGFR (0.38) EGFRIGF1RALKINSRMEN1
SCHEMBL23154188 0.87 RAF1 (0.38) EGFRIGF1RALKINSRMEN1
SCHEMBL23153854 0.86 EGFR (0.39) EGFRIGF1RALKINSRMEN1
SCHEMBL30741194 0.86 EGFR (0.39) EGFRIGF1RALKINSRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117425646-A Phosphono derivative, composition thereof and pharmaceutical application thereof 西藏海思科制药有限公司 2024-01-19 — — CN disclosed
WO-2022228547-A1 PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF 四川海思科制药有限公司 2022-11-03 — — WO disclosed
Send feedback